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Abstract
Limited evidence is available regarding the effect of par-
tially hydrolyzed whey-based formula (pHF-W) on growth 
and atopic dermatitis (AD) risk reduction in infants within 
the general infant population, and without a familial history 
of allergy as an inclusion or exclusion criterion. We reviewed 
the current evidence available from studies using pHF-W in 
the general population and summarized the data on safety 
(growth) and efficacy outcomes (reduction of AD), compar-
ing the studies side by side. A total of 8 clinical trials were 
identified from the literature search, 7 of which used the 
same pHF-W. Six out of 8 studies indicated a reduction of 
atopic manifestations using a specific pHF-W versus cow’s 
milk formula (CMF) in the first years of life. Data were sum-
marized and compared side by side for growth (3 studies) 
and efficacy (5 studies). In these diverse general popula-
tions, the results on growth and AD were consistent with 
the previous findings reported on infants with a family his-
tory of allergy, but numerous limitations to these studies 
were identified. This literature review confirms that pHF-W 
supports normal growth in infants, and suggests that the 
risk of AD may be reduced in not-fully breastfed infants 
from the general population when supplemented with a 
specific pHF-W when compared to CMF during the first 4–6 
months of life. Further studies are warranted to confirm 
these results. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Edited by: D.Y. Wang, Singapore.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
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tribution of modified material requires written permission.
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Introduction
Allergy prevalence has been rising in the last few de-
cades with atopic dermatitis (AD) being the most preva-
lent manifestation of allergy in infancy. AD affects 15–
30% of children; 60% of cases have an onset within the 
first year of life [1]. AD etiology is multifactorial, histori-
cally being associated with food allergy, and more spe-
cifically to milk allergy. AD etiology is now associated 
with genetic variants involved in skin barrier function de-
fect and inflammation, leading/predisposed to a dry skin 
with increased susceptibility to environmental triggers 
[1]. While there are multiple specific etiologic factors for 
AD, partially hydrolyzed whey-based formula (pHF-W) 
has been shown to be efficacious in reducing the risk of 
developing AD in the first years of life in infants with a 
first-degree relative affected by allergy [2–6]. Indeed, this 
population of infants is at a higher risk of developing al-
lergy than the general population, and has been selected 
for numerous clinical trials to be sufficiently powered to 
demonstrate a significant effect of formula without re-
cruiting massive numbers of infants. Hence, to date, the 
meta-analyses of pHF-W have mainly included studies 
on this high-risk population. However, about 50% of the 
infants who develop allergy do not fall in this category [7], 
and so it is not suspected and no prevention strategy is 
proposed.
During a workshop held in November 2014, we identi-
fied that the available information on the effects of pHF-
W in the general infant population was not accessible to 
the experts in the field, because it had not been published 
in English or had been presented at conferences but not 
published. We thus aimed at compiling all known avail-
able data and defining whether existing studies had deter-
mined whether pHF-W can reduce the risk of developing 
AD in the general infant population. As recently suggest-
ed by the in-depth meta-analysis of Boyle et al. [8], pool-
ing different studies performed with different products in 
the main analysis may hide the effect of specific infant 
formulas [8, 9].
In this study, we therefore identified and studied sepa-
rately all types of clinical studies, prospective or retro-
spective, randomized or not, in which infants from the 
general population were enrolled, and without a familial 
history of allergy as an inclusion or exclusion criterion. In 
all of the included studies, infants were fed with either 
intact cow’s milk formula (CMF) or pHF-W. The objec-
tive was to document and compare the studies; we thus 
summarized their results to assess the reproducibility of 
the findings on adequate growth, skin symptoms, AD, 
and/or allergy onset. This review, due to the limitation of 
the data collected, is not intended to be a systematic re-
view and meta-analysis. We thus solely present the results 
of this comparative summary, focusing on growth and 
AD risk reduction. Additionally, the strengths and limita-
tions of the studies gathered are discussed in the light of 
their results. 
Methods
Type of Studies
Randomized and non-randomized clinical trials, safety studies, 
observational studies, and epidemiologic studies with a prospec-
tive or retrospective design were included in the review. Specific 
study design was not an inclusion or exclusion criterion.
Type of Participants
Studies in which infants were selected from the general popula-
tion (and for which a family history of allergy was neither an inclu-
sion nor exclusion criterion) were eligible for inclusion.
Type of Intervention
We included any study in which infants from the general pop-
ulation (for which a family history of allergy was neither an inclu-
sion nor exclusion criterion) were fed with pHF-W versus an intact 
CMF who had had an intervention between birth and the age of 6 
months.
Type of Outcomes
Studies including outcomes related to “allergy” or “atopy” or 
“allergic” or “atopic” or “dermatitis” or “eczema” or “infantile ec-
zema” or “skin symptoms” or “sensitization” or “IgE” or “RAST” 
were eligible for inclusion. 
Search Methods 
The review was realized using available information obtained 
with the following research tools: PubMed, SCOPUS, and Google, 
and the studies previously identified in the meta-analyses, i.e., 
Boyle et al. [8], Alexander and Cabana [2], Osborn and Sinn [3], 
and Szajewska and Horvath [4]. Additionally, data were obtained 
from Nestlé Nutrition and the Nestlé Nutrition Institute, and this 
possibly led to a selection bias in this study. The authors of some 
of the studies were contacted to obtain the full poster presented at 
national or international congresses and any additional informa-
tion. 
Assessment of the Risk of Bias
The bias in the studies was assessed using methods similar to 
those recently published [6]. A low, medium, or high risk of bias 
was assigned to each study regarding selection, detection, perfor-
mance, reporting, and other biases. When unknown, the risk was 
considered “medium”.
Summary and Representation of the Data
The intention of the review is to present the studies side by side 
for similar outcomes without running a proper quantitative analy-
sis or meta-analysis, as the design of the studies varied a lot and 
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numerous risks for bias were identified. As such, data are shown 
individually using the same statistical parameters. All statistical 
analyses were performed using R v3.3.1. The proportion of allergic 
manifestations, eczema, or AD was compared between groups us-
ing Fisher’s exact test. The conditional maximum likelihood esti-
mate of the odds ratio (OR) and 95% confidence interval (CI) were 
calculated. For allergy and skin manifestations, no adjustment for 
multiplicity was applied.
The mean weights were assumed normally distributed and 
compared between groups using t tests. The mean differences are 
estimated and reported with a 95% CI. When multiple time points 
were reported, adjustment for multiplicity was performed, and 
95% family-wise CI were reported for growth. To compute the z 
scores for both sexes combined, for the trials conducted by Aki-
moto et al. [10, 11] and Wen et al. [17], these scores were calcu-
lated with the World Health Organization (WHO) tables for boys 
and girls separately, and then averaged. The mean differences in z 
scores for both sexes combined are provided in Exl et al. [7]. 
Dealing with Missing Data
Intention to treat and per protocol analysis were not separated 
or mentioned in most of the studies. We thus show, when available, 
the ratio between the number of events and the total number of 
participants reported at the different time points, the OR for aller-
gy-related parameters, and the z scores (when available) for weight 
and length.
Results
Study Selection
The overview of the 8 studies assessed in this review is 
presented in Table 1, and study designs and details on ex-
cluded studies in the online supplementary material (see 
www.karger.com/doi/10.1159/000489861 for all online 
suppl. material). Out of these 8 studies, 7 used the same 
infant formula, a 100% pHF-W from Nestlé: Akimoto et 
al. [10, 11], Exl et al. [7, 12], Fukushima et al. [13], Hart-
man et al. [14], Ngamphaiboon [15], Schmitz et al. [16], 
and Wen et al. [17]. The eighth, performed by Moran 
[18], used a mix of pHF-W/casein (60/40) (Mead John-
son) and could not be summarized due to the lack of doc-
umentation on allergy-related parameters (only milk-
specific IgG in the serum was reported); the authors also 
mentioned that the study was not powered to look at AD. 
Among the remaining 7 studies performed with the 
same 100% pHF-W, 2 were not included in the reanalysis. 
The first, by Hartman et al. [14] did not provide sufficient 
quantitative data. The authors looked at growth between 
birth and the age of 6 months, and mentioned that mean 
growth velocity was similar across the different formula-
fed groups and did not significantly differ from the exclu-
sively breastfed (BF) group over the 6-month period of 
the study. In addition, despite a significant reduction of 
the rate of allergic manifestations for the pHF-W groups 
compared to the CMF group after 4 months of age, the 
study did not provide frequency data to allow for recalcu-
lating the effect [14]. The second, by Schmitz et al. [16], 
involved a very short intervention limited to the first 5 
days of life, and did not provide sufficient numerical data 
for AD.
Five of the 7 studies were reanalyzed for the risk of de-
veloping AD, eczema, or allergic skin symptoms: Akimo-
to et al. [10, 11], Exl et al. [7, 12], Fukushima et al. [13], 
Ngamphaiboon [15], and Wen et al. [17]. Only 3 studies 
provided sufficient data for growth assessment: Akimoto 
et al. [10, 11], Exl et al. [7, 12], and Wen et al. [17]. The 
study performed in Thailand by Ngamphaiboon [15] had 
to be excluded as it did not comment on growth, due to 
its retrospective design that could not guarantee sched-
uled visits. In addition, Fukushima et al. [13], while no 
differences in growth were observed between groups at 4 
months, could not be included due to the lack of numer-
ical data.
Effect of pHF-W on Growth
As discussed above, 3 of the 7 studies identified as us-
ing the same pHF-W consistently documented growth 
and safety data. The remaining 4 studies were excluded 
from the following summary.
Published Results on Growth
In Exl et al. [7, 12], health outcomes are recorded in 
detail and described. The authors mentioned that growth 
data (including weight, length, head circumference, and 
body mass index) were recorded by the physicians at 
scheduled visits according to standardized methods. Ref-
erence values were obtained from WHO standards avail-
able at that time [19, 20]. No noticeable differences were 
observed in weight-for-age and length-for-age z scores 
between the 2 cities from birth to 6 months, and adequate 
growth was observed in all groups compared to WHO 
standards [19, 20]. The only significant confounder ob-
served on growth was “smoking mother”, associated with 
a lower weight (of 120 g at 3 months and 160 g at 6 months) 
compared to “non-smoking mother.”
In Wen et al. [17], in which growth parameters (weight, 
length, and head circumference) at the ages of 1, 3, 6, 9, 
and 12 months were recorded, no statistical significant 
differences across the 3 groups were observed while using 
a global testing procedure. At 6 months, the weight was, 
on average, 0.2 kg higher in the CMF group compared to 
the pHF-W group, i.e., 7.9 ± 0.9 kg in the pHF-W group, 
8.1 ± 0.9 kg in the CMF group, and 8.0 ± 0.9 kg in the BF 
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group. At 6 months, length was 67.2 ± 2.5 cm in the pHF-
W group, 68.1 ± 2.4 cm in the CMF group, and 67.6 ± 2.3 
cm in the BF group.
Akimoto et al. [10] did not find any significant differ-
ence in body weight at 4 months between pHF-W and the 
infants fed either CMF or breast milk. Infants were 7,028.9 
± 729.4 g (n = 35) in the pHF-W group versus 7,214.2 ± 
814.2 g (n = 91) in the control CMF group combined with 
the exclusively BF group (n = 62 + 29, respectively). Even 
though the average was 200 g more in the CMF group, 
differences were not significant, mostly due to the wide 
spread of the data observed in the compared groups. 
While the 2 groups, CMF and BF, were not combined in 
the original paper, the weights were not reported. 
Summary of the Results
Figure 1 gives an overview of all the available results 
presented as z scores compared to WHO standards or to 
a CMF group when individual data per group are not 
available. These data indicate that the growth (both 
weight and length) of the infants enrolled in these studies 
follows the WHO growth standard. 
The differences between the 2 groups, i.e., BF ± pHF-
W (n = 466) and BF ± CMF (n = 535), for the weight-for-
age and length-for-age z scores at 3 and 6 months from 
the study by Exl et al. [7] showed no difference between 
the 2 groups.
In Wen et al. [17], the growth measurements were 
done at 3, 6, 9, and 12 months of age. The weight results 
from the pHF-W group (n = 653) closely tracks the values 
observed for the BF group (n = 874). At every time point, 
the pHF-W group mean values are lower than the CMF 
group (n = 246), but within the WHO standard ± 1 stan-
dard deviation (SD). 
Finally, only the 4-month growth data were reported 
in the trial conducted by Akimoto et al. [10, 11] for the 
pHF-W (n = 35), CMF (n = 62), and BF (n = 29) groups. 
As shown in Figure 1, the mean weight-for-age z score for 
the pHF-W group was lower than the CMF group, both 
being again within the range of the WHO standard.
Effect of pHF-W on Allergy and AD Risk Reduction
Five of the 7 studies using pHF-W were sufficiently 
documented for the allergic manifestations and/or AD 
symptoms in the different intervention groups. In all 
studies, the family history of allergy was recorded. Most 
of them mentioned that the frequency of allergic parents 
and/or siblings was not significantly different in the CMF 
and pHF-W groups. However, 3 studies, Fukushima et al. 
[13], Ngamphaiboon [15], and Exl et al. [7], confounded 
their results with the increased risk of developing AD or 
other allergic manifestations. These 3 studies also men-
tioned that a family history of allergy was a main risk fac-
tor for atopic symptoms in the first year of life but the 
effect of the specific pHF-W was still seen after correcting 
for the allergy risk.
Published Results on Allergic Symptoms Including 
AD
Based on the data reported in the study performed in 
Switzerland by Exl et al. [7], a significant decrease in AD 
incidence was observed in the pHF-W group at 6 months 
when the authors applied a standard statistical test (11.9% 
in the non-intervention group vs. 7.0% in the interven-
tion group).
In Wen et al. [17], the AD occurrences in the BF and 
pHF-W groups (27.00 vs. 27.26%) were similar. The inci-
dence of AD in both the BF and pHF-W groups was sig-
nificantly lower than in the CMF group (34.96%). These 
pairwise comparisons between groups were computed 
based on the data provided, and were not adjusted for 
multiple comparisons. This Chinese study suggests that a 
specific pHF-W reduces the risk of developing AD in the 
general infant population when compared to intact CMF. 
The results are also significant for the cumulative inci-
dence of allergic manifestations, but are highly biased by 
the high prevalence of AD versus other allergic manifes-
tations in this age group (Fig. 2).
In the trial reported in Japanese by Akimoto et al. [10], 
it is not clearly stated if the skin symptoms observed were 
related to AD or whether all types of skin symptoms were 
measured and included. However, in the English version 
of this study [11], the authors show the prevalence of al-
lergic skin and respiratory symptoms at 4 and 12 months 
of age. A total of 3/35 and 4/33 infants were affected by 
skin allergic symptoms in the pHF-W group at 4 and 12 
months, respectively. At the same time points, 21/62 and 
20/59 infants were affected by skin allergic symptoms in 
the CMF group and 5/29 and 13/27 in the BF group, re-
spectively. The authors observed a significant decrease of 
allergic symptoms (respiratory and skin allergic symp-
toms) in the pHF-W group at 4 months (OR 0.19; 95% CI 
0.03–0.70) and 12 months (OR 0.27; 95% CI 0.06–0.94) 
compared to the CMF group, and at 12 months compared 
to the BF group (OR 0.15; 95% CI 0.03–0.61). Only 3/119 
subjects reported allergic respiratory symptoms at 12 
months. In this study, the incidence of skin symptoms 
was followed up to 36 months of age, but was only sig-
nificant at 1 year of age. The greatest difference was in-
deed observed at 1 year of age, with 5/33 subjects (15.2%) 
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presenting skin symptoms in the pHF-W group versus 
37/86 (43%) in the CMF group (OR 0.24; 95% CI 0.07–
0.71). 
In the study by Ngamphaiboon [15], the average age 
of the diagnosis of allergic diseases was 14.7 months (2 
weeks to 5 years). The most prevalent clinical presenta-
tion in the first year of life was AD. The cumulative inci-
dence of allergic manifestations was significantly reduced 
by using pHF-W compared with BF (OR 0.23; 95% CI 
0.160–0.314) and increased by using CMF compared with 
BF (OR 1.66; 95% CI 1.396–1.957) when adjusted for sex 
and a family history of atopy. The direct comparison of 
the proportion of cumulative incidences between the 
CMF and pHF-W groups suggests that 30.3% of the BF 
group were atopic compared to 42.3% of the CMF group 
and 11.3% of the pHF-W group. This was also significant 
when adjusting for sex and a family history of atopy.
In the study by Fukushima et al. [13], at 4 months of 
age, the infants mixed-fed with breast milk and pHF-W 
showed a significantly lower prevalence of allergic mani-
festations and eczema than those fed breast milk comple-
mented with CMF. No significant differences were found 
compared to the group that was fed exclusively breast 
milk. A significant decrease in eczema was found in the 
pHF-W group when compared to the CMF group at 12 
months (OR 0.31; 95% CI 0.13–0.75). The protective ef-
fect was not significant anymore at 24 months (OR 0.57; 
95% CI 0.24–1.37).
Summary of the Study Results
The results of study data are summarized in Figure 2 by 
comparing AD, eczema, skin manifestations, and/or aller-
gic manifestations between pHF-W and CMF groups in the 
5 selected studies. When possible, we focused on the cumu-
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al. [17], means and SD are represented for breastfed (BF) and formula-fed infants (CMF or pHF-W). For Exl et 
al. [7], the mean differences between pHF-W and CMF (i.e., CMF – pHF-W) with a 95% confidence interval are 
shown, as only differential z scores were available.
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lative incidence of AD or eczema [7, 15, 17], but all available 
data are presented. Our data were based on the data re-
ported in the papers but were not adjusted for confounders 
such as a family history of allergy or multiple testing. 
The Wen et al. [17] and Ngamphaiboon [15] studies 
mentioned that AD was the main allergic symptom re-
corded in the first years of life. Approximately 95% of the 
recorded allergy cumulative incidence in Wen et al. [17] 
consisted of AD manifestations; this study involves AD 
and atopic diseases whereas Ngamphaiboon [15] covered 
atopic disease only.
In Akimoto et al. [10, 11], the effect of pHF-W versus 
CMF on skin symptoms is shown. However, in Fukushi-
ma et al. [13], while eczema and overall allergies are re-
ported, only prevalence ORs are reported in the forest 
plot (Fig. 2) because the exact prevalence ratio was not 
provided in the related publication.
When comparing pHF-W to CMF (Fig. 2), the ORs are 
in favor of the pHF-W for allergic manifestations (Wen 
et al. [17]: OR 0.68; 95% CI 0.50–0.94, p = 0.019; Ngam-
phaiboon [15]: OR 0.17; 95% CI 0.12–0.24, p < 0.001) and 
AD (Wen et al. [17]: OR 0.70; 95% CI 0.50–0.97, p = 0.027; 
Exl et al. [7]: OR 0.56; 95% CI 0.36–0.87, p = 0.007). Fu-
kushima et al. [13] and Akimoto/Iikura et al. [10/11] also 
show a significant effect of pHF-W on allergy or eczema, 
mostly in the first year of life (Fig. 2). No significant re-
duction of the risk of developing eczema at 24 months 
and of developing overall allergies at 18 months were ob-
served in Fukushima et al. [13]. Comparison of the pHF-
W or CMF group to the BF group was also performed; 
results are described in the supplementary results and 
shown in online supplementary Figure 1. 
Study Bias and Limitations
Figure 3 and Table 1 summarize the bias identified in 
these studies. The selection of the participants was not 
randomized in some of the studies, as shown in Table 1. 
In some studies, the mothers were free to choose their 
Ngamphaiboon. (2006) – atopic diseases up to 5 years
Exl et al. (2000) – AD at 6 months
Fukushima et al. (1997) – eczema at 12 months
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Fukushima et al. (1997) – overall allergies at 12 months
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Fukushima et al. (1997) – overall allergies at 24 months
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Iikura et al. (1995) – skin symptoms at 4 months
Iikura et al. (1995) – skin symptoms at 12 months
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Fig. 2. Effect of infant feeding on the cumulative incidence of eczema, skin symptoms, atopic diseases, or AD: 
differential effects of pHF-W versus CMF. For Fukushima et al. [13], only odds ratios (ORs) with 95% confidence 
intervals (CIs) of prevalence are reported. 
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preferred formula type according to study protocol guide-
lines [10, 11, 15, 17]. When randomized, the use of ran-
dom sequence generation or allocation concealment is 
not described, suggesting a medium-to-high risk of selec-
tion bias in these studies overall. Only 3 studies [14, 16, 
18] were clearly mentioned as double-blinded, but in 
these, the data on growth or AD were not available from 
the publication. One study was single-blinded [17], one 
was a retrospective observational study [15], and the oth-
ers did not report on the blinding of the participants or 
health care practitioners. Similarly, in all of the studies, 
the blinding of the outcome assessment/the method of 
data collection was not reported in the publication, sug-
gesting a medium-to-high risk of a performance and de-
tection bias. The type of outcome reported is also not con-
sistent across studies. Allergy, AD, and eczema are fre-
quently used interchangeably but they are different 
entities. Allergy regroups symptoms that are linked to an 
adverse reaction to an environmental or food allergen 
that is innocuous to non-allergic individuals. The symp-
toms of allergy can affect different organs such as the 
lungs, gastrointestinal tract, and skin, or even lead to car-
diovascular manifestations in the case of anaphylaxis. AD 
is a chronic inflammation of the skin characterized by 
patches of relapsing itchy rashes and lesions. As men-
tioned in the Introduction, AD etiology is multifactorial 
and is one of the manifestations of food allergy [1]. Ec-
zema is an entity that regroups numerous skin manifesta-
tions, including, but not limited to, AD. The limited in-
formation regarding the exact definition of the investi-
gated outcomes in some of the studies referred in this 
review is also to be considered as a possible bias.
It is possible that there was selective reporting in all of 
the studies, and this is clearly observed when comparing the 
publications by Akimoto et al. [10] and Iikura et al. [11] on 
the same trial. The selective reporting of positive results 
certainly led to a bias in this review as non-positive findings 
are frequently not reported in publications, mostly due to 
the low interest of readers and journals for negative data. 
When present, negative data are only cited as non-signifi-
cant, limiting access to the numerical data. However, out of 
the studies that fall in the category of data not being report-
ed, Moran [18] and Schmitz et al. [16] did not look at the 
outcome due to not being powered enough or not finding 
any significant effect, while Hartman et al. [14] mentioned 
a significant protective effect of the pHF-W over the CMF.
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As far as other biases are concerned, such as concomi-
tant nutritional recommendations other than the tested 
formula, the absence of peer-reviewed publication in an 
international journal, or the sponsorship provided by the 
company manufacturing the formula, all but 2 of the 
studies were identified as having a higher risk of bias.
Additionally, while all identified studies using pHF-W 
could be included in this review, a selection bias exists due 
to the access and information obtained from one-manu-
facturer internal data. Altogether, these analyses suggest 
that there is interesting data on growth and AD risk re-
duction with PHF-W supplementation in the general in-
fant population, but these data need to be interpreted in 
the light of the above limitations.
Discussion
Breastfeeding is the ideal feeding option for infants. 
The introduction of formula as a breast milk substitute 
should only be suggested if the mother cannot or does not 
want to breastfeed. Currently, pHF-W is approved by the 
European Food Safety Authority (EFSA) and the US Food 
and Drug Administration (FDA) for use as a routine in-
fant formula for any healthy term infant.
In this review, we aimed at compiling the evidence re-
garding growth and allergic manifestations in infants 
from the general population (for which a family history 
of allergy was neither an inclusion nor an exclusion crite-
rion) who were supplemented with pHF-W during the 
first 4–6 months of life.
We identified 8 studies fitting our selection criteria, 
regrouping a total of 7,752 infants, 2,222 of which were 
fed pHF-W or pHF-W/casein (60/40). Of these 8, 6 dem-
onstrated a significant decrease of AD or allergic/skin 
manifestations with pHF-W (Akimoto et al. [10, 11], Exl 
et al. [7, 12], Fukushima et al. [13], Hartman et al. [14], 
Ngamphaiboon [15], and Wen et al. [17]). Five displayed 
sufficient data on allergy symptoms to be reported, total-
ing 1,757 infants fed with the same pHF-W (Akimoto et 
al. [10, 11], Exl et al. [7, 12], Fukushima et al. [13], Ngam-
phaiboon [15], and Wen et al. [17]). Regarding growth, 3 
of these 5 allowed us to reanalyze the effect of this spe-
cific pHF-W on infant growth by incorporating data on 
1,154 infants (Akimoto et al. [10, 11], Exl et al. [7, 12], and 
Wen et al. [17]). The studies show weights in the pHF-W 
group to be similar to the BF group and in the range of 
WHO standards. While a trend toward a 200-g increase 
in the CMF group (compared to the pHF-W group) was 
seen in 2 studies, suggesting a trend toward slight over-
nutrition after the age of 4 months, the averages are with-
in the normal range the SDs are quite large, and comple-
mentary foods are usually already introduced. A larger 
study would be needed to assess the clinical relevance of 
this observation about CMF.
A meta-analysis at 12 months that included the results 
from Fukushima et al. [13], Wen et al. [17], and Akimoto 
et al. [10] was performed on eczema, AD, and allergic skin 
symptoms, respectively, and showed a significant protec-
tive effect in favor of pHF-W compared to CMF (online 
suppl. Fig. 2). Indeed, the effect size (a 30–40% risk reduc-
tion at 1 year of age) is comparable to what has been de-
scribed in a meta-analysis of infants with a family history 
of AD [2–4, 6]. However, due to the variability of study 
design, the different allergic outcomes, the various infant 
ages at which allergic outcomes were measured, and the 
possible study selection bias identified in this review, the 
relevance of the meta-analysis remains low. Indeed, the 
criteria for the identification of atopy, allergic manifesta-
tions, or AD differed, and was not clearly or uniformly 
described in all studies. For this reason, individual study 
results were reported rather than performing a meta-
analysis. In addition, the US and European agencies (US 
FDA and EFSA) usually perform their scientific assess-
ment for clinical substantiation on multiple individual 
studies using the same product and clinical outcomes 
rather than performing meta-analyses.
A first interesting observation of this analysis relates to 
the geographic distribution of the included studies: 1 in 
Europe [7], 1 in China [17], 1 in South East Asia [15], 1 
in the USA [14], and 2 in Japan [10, 11, 13]. This indicates 
the wide geographical interest in reducing the risk of de-
veloping atopic diseases by nutritional intervention. It 
also suggests that ethnic differences between populations 
and environmental components may not necessarily 
compromise the preventive effect of pHF-W on AD or 
allergic manifestations in the first year of life.
This multiple individual study report is subject to some 
limitations inherent to the design of the studies. As always, 
the BF reference groups were not randomized. In some 
studies, breastfeeding was exclusive, while mixed feeding 
was present in some others. Of note, in 2 studies [7, 10], the 
authors combine exclusively BF infants, formula-fed in-
fants, and partially BF infants in the CMF and pHF-W 
groups. In Akimoto et al. [10], the CMF and BF groups 
were combined in a single control group, thus rendering 
the interpretation more difficult. It is also highly likely that 
mothers switched formula in the retrospective study per-
formed in Thailand [15]. In this study, the requirement for 
feeding exclusively with 1 type of formula is not reported.
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Interestingly, the effect size observed with pHF-W 
supplementation is similar to what was observed in trials 
performed in populations selected with a first-degree rel-
ative with allergic disease [2–6]. On explanation could be 
that, in the general infant population with the genetic bias 
being weaker than in infants with a first-degree relative 
with allergic disease, the effect of a change like pHF-W 
versus CMF may have a better or similar effect due to be-
ing less confounded by genetic factors that would favor 
the development of allergic symptoms regardless of nu-
tritional or environmental pressures. On the other hand, 
this could have been due to the unequal distribution of 
allergy risk in the different groups. A subgroup analysis 
of these studies, separating infants according to risk, may 
help answer whether the effect of pHF-W is similar in in-
fants with and without ≥1 first-degree relatives present-
ing allergy. While the family history of allergy was record-
ed, subgroup analyses were mostly not performed, and 
results were confounded for allergy risk in 3 of the studies 
[7, 13, 15]. However, these studies did report a significant 
reduction of the risk of developing AD even once the data 
were confounded with the family allergy risk. This type of 
analysis is particularly important for non-randomized 
trials and/or when the mothers were made aware of the 
benefit of pHF-W on allergy risk reduction as in Wen et 
al. [17]. In non-randomized studies, there is also a high 
risk that mothers breastfeed for longer or give pHF-W if 
symptoms start while they are still fully breastfeeding. 
This may explain, in part, the effect observed in the non-
randomized retrospective trial performed by Ngamphai-
boon [15].
Specific late introduction of complementary allergenic 
food was recommended in Exl et al. [7]. In this study, the 
authors measured the effect of a dietary recommendation 
on AD risk reduction as they combined a recommenda-
tion to introduce pHF-W feeding when exclusive breast-
feeding was not possible with a dietary recommendation 
for introducing complementary foods [8]. This recom-
mendation of late introduction of highly allergenic food 
only in the pHF-W group may have partly influenced AD 
incidence.
Delaying solid food introduction including allergenic 
foods after the age of 1 year is no longer recommended 
for preventing allergic diseases [21]. Other environmen-
tal factors may influence the incidence of allergic mani-
festations as local habits may modify allergic susceptibil-
ity even if cities are close to each other, like in the study 
by Exl et al. [7]. Indeed, von Mutius et al. [22–24] have 
shown that, even in the same village, early life exposure 
to dairy farms influences the prevalence of asthma and 
allergic rhinitis in children, thereby highlighting the ne-
cessity for proper randomization. Most of the studies did 
not report on compliance, and the dropout rate (with/
without reason) was not always mentioned. Intention-to-
treat (ITT) and per-protocol (PP) analyses were discussed 
in the Exl et al. [7] study only. Finally, there was not the 
same amount of data available in the different trials and 
2 of the works were never peer-reviewed and only submit-
ted as abstracts. Altogether, and knowing these limita-
tions, this multiple individual study analysis ascribes val-
ue to this existing data and provides additional relevant 
results for growth, allergy risk reduction, and AD in the 
general infant population.
In conclusion, the available studies suggest that, when 
breastfeeding is not possible, feeding a specific pHF-W 
instead of intact CMF may reduce the risk of developing 
atopic manifestations, including AD, in the general infant 
population, while still supporting age-appropriate infant 
growth. A well-designed, randomized, double-blinded 
study or an independent, single-blinded study comparing 
supplementation with pHF-W versus CMF is warranted 
to confirm these results. 
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